Arbutus Biopharma
Arbutus Biopharma Corporation is a Canadian clinical-stage biopharmaceutical enterprise specializing in the discovery, development, and commercialization of innovative therapeutics for treating chronic hepatitis B virus (HBV) infection and coronavirus diseases, utilizing proprietary lipid nanoparticle (LNP) delivery technology. The company conducts advanced clinical trials evaluating antiviral drug candidates and RNA interference (RNAi) therapeutics designed to achieve a functional cure for hepatitis B. Its core business operations encompass biopharmaceutical research, clinical trial execution, LNP drug delivery platform development, and pharmaceutical formulation. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its research activities through collaborative licensing agreements, milestone payments, and public equity offerings. Arbutus Biopharma holds a pioneering market position in lipid nanoparticle drug delivery technology and hepatitis B antiviral drug development. The company is headquartered in Warminster, Pennsylvania, United States, with corporate registration in Canada, and its common stock trades on the Nasdaq Global Select Market under the ticker ABUS.
2 of the funds FundTelligence covers report a position in Arbutus Biopharma.
- Legal name
- ARBUTUS BIOPHARMA CORP
- Sector
- Health Care
- Country
- Canada
- Funds holding it
- 2
- Exposure themes
- Genetic Medicine, Precision Medicine & Genomics, RNA Therapeutics
Funds holding Arbutus Biopharma
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)